Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept for Hidradenitis Suppurativa
NCT00107991Phase 2Completed
- Sponsor
- University of Pennsylvania
- Start
- Apr 2005
- Primary completion
- Aug 2008
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 2, open-label, single-arm trial of etanercept in hidradenitis suppurativa (HS), sponsored by University of Pennsylvania. Primary endpoints: 50% Reduction in Physician's Global Assessment Score at 12 weeks and Safety and Adverse Events at 18 weeks. Started Apr 2005; status: completed.
02
Drugs
etanercept
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT00107991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00107991.